<div><div><span><p><strong><span>On October 24, 2025, Theriva Biologics announced a prospectus supplement for a $4,019,597 stock offering.</span></strong></p><span> </span><p><strong><span>Key Highlights:</span></strong></p><span> </span><ul><li><span>Offering involves up to $4,019,597 in common stock sales.</span></li><li><span>Sales to be conducted through A.G.P./Alliance Global Partners.</span></li><li><span>Sales Agent to receive up to 3% commission on sales.</span></li><li><span>Stock sales classified as &#34;at the market offering&#34; under SEC rules.</span></li></ul><p><span>Original SEC Filing: </span>Theriva Biologics, Inc. [ TOVX ] - 8-K - Oct. 24, 2025</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

TOVX

<p>Theriva Biologics has filed a prospectus supplement for a stock offering totaling $4,019,597. The offering will involve the sale of common stock through A.G.P./Alliance Global Partners, with the sales agent receiving up to a 3% commission. This stock sale is classified as an "at the market offering" under SEC rules, as per the original SEC filing dated October 24, 2025.</p>

Theriva Biologics Files Prospectus for Stock Offering